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Neuromuscular junctions (NMJs) are synapses that transmit impulses from motor neurons to skeletal muscle fibers leading to muscle
contraction. Study of hereditary disorders of neuromuscular transmission, termed congenital myasthenic syndromes (CMS), has helped
elucidate fundamental processes influencing development and function of the nerve-muscle synapse. Using genetic linkage, we find 18
different biallelic mutations in the gene encoding glutamine-fructose-6-phosphate transaminase 1 (GFPT1) in 13 unrelated families with
an autosomal recessive CMS. Consistent with these data, downregulation of the GFPT1 ortholog gfpt1 in zebrafish embryos altered
muscle fiber morphology and impaired neuromuscular junction development. GFPT1 is the key enzyme of the hexosamine pathway
yielding the amino sugar UDP-N-acetylglucosamine, an essential substrate for protein glycosylation. Our findings provide further
impetus to study the glycobiology of NMJ and synapses in general.Introduction
Efficient signal transmission from the motor neuron to
a skeletal muscle fiber at the neuromuscular junction
(NMJ) is a prerequisite for muscle contraction.1 When an
action potential reaches the presynaptic button, the neuro-
transmitter acetylcholine (ACh) is released into the
synaptic cleft. Binding of ACh to nicotinic acetylcholine
receptors (AChR) at the motor end plate of the muscle fiber
induces opening of the cation selective ion channels
leading to depolarization of the muscle fiber, the release
of calcium ions from the sarcoplasmic reticulum, and ulti-
mately muscle contraction. A number of different neuro-
logical conditions can result from impaired neuromuscular
transmission, varying from poisoning with botulinum and
snake venom toxins through the autoimmune mediated1Institute of Cell Biology, Eidgeno¨ssische Technische Hochschule (ETH) Zu¨rich
fa¨lische Technische Hochschule (RWTH) Aachen, 52074 Aachen, Germany; 3In
3BZ, UK; 4Friedrich-Baur-Institut, Department of Neurology, Ludwig Maximi
Helmholtz Zentrum Mu¨nchen, German Research Center for Environmenta
Hospital Alexandrovska, 1431 Sofia, Bulgaria; 7Neurosciences Group, Weath
University of Oxford OX3 9DU, UK; 8Servicio de Neurologia, Hospital La Fe and
degenerativas (CIBERNED), 46009 Valencia, Spain; 9Unitat de Patologia Neuro
(Barcelona), Spain; 10Department of Neurology, Tehran University of Medic
Genetics Center, 14667 Tehran, Iran; 12Neuropathology Laboratory, Toos Hos
Anaesthesiology, Azienda Ospedaliera Universitaria (A.O.U.) ‘‘G. Martino’’, 981
ative Care, Hanse-Klinikum, 18435 Stralsund, Germany; 15Institute of Human
sion of Neuropaediatrics and Muscle Disorders, University Medical Center, 79
Essen, 45122 Essen, Germany; 18Universite´ Pierre et Marie Curie (UPMC) -
S974, Institut National de la Sante´ et de la Recherche Me´dicale (INSERM) U 97
de Myologie, Universite´ Pierre et Marie Curie - Paris 6, 75013 Paris, France; 19De
405 30 Gothenburg, Sweden; 20Neuromuscular Center, Sahlgrenska Universit
France; 22University Children’s Hospital, Technical University Dresden, 01307
sioning Group (CMS NCG), Department of Clinical Neurology, John Radcliffe
24These authors contributed equally to this work
*Correspondence: jan.senderek@cell.biol.ethz.ch (J.S.), hanns.lochmuller@ncl
DOI 10.1016/j.ajhg.2011.01.008. 2011 by The American Society of Human
162 The American Journal of Human Genetics 88, 162–172, FebruaryNMJ disorders such as myasthenia gravis and the
Lambert-Eaton myasthenic syndrome to the hereditary
congenital myasthenic syndromes (CMS; for a discussion
of genetic heterogeneity of CMS, see MIM 608931).2,3
These conditions may lead to generalized paralysis and
respiratory failure and, if untreated, can be life threatening.
The neuromuscular junction is probably the most studied
synapse, but many aspects of its formation, maturation,
stabilization, and functional efficacy remain incompletely
understood.4
During the last two decades, research into the molecular
causes of CMS has led to the identification of mutations in
several genes and has greatly influenced established or in-
ferred concepts of NMJ pathophysiology.3 Here, we used
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CBa limb-girdle pattern ofmuscleweakness combinedwith the
presence of tubular aggregates on muscle biopsies (myas-
thenia, limb-girdle, with tubular aggregates [MIM
610542]).5,6 Individualswith this conditionhave a recogniz-
able pattern of weakness of shoulder and pelvic girdle
muscles (Figure 1), sparing of ocular or facialmuscles, neuro-
physiologic signs of NMJ dysfunction (decrement of the
muscle action potential with repetitive nerve stimulation),
and a good treatment response to acetylcholinesterase
(AChE) inhibitors. Genetic evaluation of these families re-
vealed pedigrees typical of an autosomal recessive trait, but
the underlying genetic defect had not yet been identified.
We localized and refined the genetic interval on chromo-
some 2 by homozygosity mapping, identified mutations in
the gene encoding glutamine-fructose-6-phosphate trans-
aminase 1 (GFPT1) as a so far unrecognized cause of CMS,
and recapitulatedhumanpathology inzebrafishmorphants.
GFPT1 catalyzes the transfer of an amino group from
glutamine onto fructose-6-phosphate, yielding glucos-
amine-6-phosphate (GlcN-6-P) and glutamate. This transa-
midase reaction has been identified as the first and rate-
limiting step of the hexosamine biosynthesis pathway,
which is the obligatory source of essential amino sugars for
the synthesis of glycoproteins, glycolipids, and proteogly-
cans (FigureS1, availableonline).7AsmanykeyNMJproteins
are glycosylated8 our data will pave the way for new studies
on the functional integrity of the neuromuscular synapse.
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Figure 1. Phenotype of CMS Patients in this Study and Linkage
to Chromosome 2p12-p15
(A) Relative frequency of signs and symptoms in our patient
cohort (n ¼ 23). The following abbreviations are used: RNS, repet-
itive nerve stimulation; EMG, electromyography; CK, creatine
kinase.
(B) Patient LGM10.4 showing proximal muscle weakness and
hyperlordotic posture at prolonged arm elevation.
(C) Patient LGM12.3 showing scapular winging.
(D) Genome-wide linkage analysis of family LGM3. Analysis was
performed with MERLIN with the assumption of autosomal-reces-
sive inheritance with complete penetrance and a disease allele
frequency of 0.001.Subjects and Methods
Patients
Pedigrees and countries of origin of 16 CMS families are
shown in Figure S2 and a synopsis of clinical findings is
shown in Figure 1. Five families, LGM3, LGM4, LGM13,
LGM15,andLGM16,havebeenpublishedearlier.9,10Venous
blood samples were obtained from the patients as well as
from their unaffected parents and siblings. Genomic DNA
was isolated with the Wizard Genomic DNA Purification
Kit (Promega,Mannheim,Germany) according to themanu-
facturer’s recommendations. All genes that are known to
cause CMS when mutated (CHAT [MIM 118490], CHRNA1
[MIM 100690], CHRNB1 [MIM 100710], CHRND [MIM
100720], CHRNE [MIM 100725], COLQ [MIM 603033],
DOK7 [MIM 610285], RAPSN [MIM 601592], MUSK [MIM
601296], SCN4A [MIM 603967], LAMB2 [MIM 150325],
and AGRN [MIM 103320]) and two functional candidate
genes (CNTN1 [MIM 600016] and AChE [MIM 100740])
were excluded by direct sequencing or by haplotype anal-
ysis.11 All studies were carried out with informed consent of
the probands or their legal guardians and were approved by
institutional ethics review boards inMunich andNewcastle.Reagents
If not stated otherwise, all chemicals were obtained from
Sigma-Aldrich (Munich, Germany). Sequences of oligonu-
cleotide primers are available upon request.The AmericaLinkage Analysis
In order to identify the disease locus, we performed homo-
zygosity mapping12 by genome-wide genotyping of SNP
for family LGM3 using the Illumina 300K chip (Illumina,
San Diego, CA). Multipoint linkage analysis was performed
with MERLIN13 assuming autosomal recessive inheritance,
a frequency of the deleterious allele of 0.001, and complete
penetrance. For targeted linkage and homozygosity anal-
ysis of chromosome 2p12-p15, DNA samples from families
LGM1, LGM2, LGM5, LGM6, LGM7, LGM8, LGM10,
LGM11, and LGM12 were analyzed with short tandem
repeat (STR) markers. Twenty-three markers were retrieved
from the National Center for Biotechnology Information
UniSTS database, and four new polymorphisms weren Journal of Human Genetics 88, 162–172, February 11, 2011 163
identified by using the Repeat-Masker program. PCR
primers for new STRs were designed by the Primer3
program. Sense primers were labeled with FAM fluoro-
phores (MWG Biotech, Ebersberg, Germany) for detection
on an ABI 377 DNA sequencer (Applied Biosystems, Foster
City, CA). Multipoint LOD scores were calculated with the
GeneHunter v2.1r5 program14 in the EasyLinkage software
package.15 The genomic localization of the markers was
derived from the Marshfield map and the University of
California Santa Cruz (UCSC) human genome assembly.
Candidate-Gene Analysis
For selection of candidate genes in the linkage region on
chromosome 2p12-p15, we used the February 2009 freeze
of the UCSC human genome assembly. Forty-six known
genes and uncharacterized transcripts were located in the
5.92 Mb interval between STR markers D2S296 and
D2S2977 (Table S1). We ranked the annotated sequences
with respect to neuromuscular junction and skeletal
muscle biology and disease. We used information from
public databases and characterized proteins in silico by
BLAST alignments to protein database entries and compar-
ison of domain composition and organization with the
SMART algorithm. We also investigated positional candi-
date genes for structural and functional homology with
the known proteins involved in CMS and related disorders.
Sixteen genes were screened for mutations (Table S1).
Primer pairs for each exon, including flanking intron
sequences, were designed from genomic sequence with
Primer3 (for GFPT1: genomic DNA AC114772.5; mRNA,
NM_002056.2 and AF334737.1 [muscle isoform16];
protein, NP_002047.2 and AAK15342.1 [muscle iso-
form16]). PCR products were directly sequenced with ABI
PRISM 3730 DNA Analyzer and BigDye Terminator Cycle
Sequencing Kit version 1.1 according to the protocols of
the manufacturer (Applied Biosystems). Sequence variants
were identified by visual inspection of electropherograms.
Control samples were screened by restriction enzyme
digestion or pyrosequencing. PCR primers for pyrose-
quencing were designed with Primer SNP Design version
1.01 software (Biotage, Uppsala, Sweden). Pyrosequencing
was carried out as defined by the supplier on a PSQ HS96A
instrument (Biotage). Samples were analyzed with the PSQ
HS96A version 1.2 software (Biotage).
Plasmid Constructs
Human GFPT1 cDNA was amplified from human skeletal
muscle cDNA and inserted into the EcoRI and NotI sites
of the pCMV-Myc vector (Clontech, Mountain View, CA)
allowing expression of human GFPT1 with an N-terminal
Myc-tag. For enzyme activity assays, we cloned the
GFPT1 constructs into the pEGFP-N1 plasmid (Clonetech)
and simultaneously removed the EGFP open reading frame
to obtain untagged GFPT1. The mutants p.Thr15Ala,
p.Asp43Val, p.Arg111Cys, p.Ile121Thr, p.Asp348Tyr,
p.Arg434His, and p.Met492Thr were generated by site-
directed mutagenesis with mismatch primers.17 Orienta-164 The American Journal of Human Genetics 88, 162–172, Februarytion of the inserts and absence of PCR-induced mutations
were verified by sequencing.
Cell Culture
HEK293, C2C12, and SW13 cells were cultured in Dulbec-
co’s Modified Eagle’s medium (DMEM) supplemented with
10% fetal calf serum. Primary human myoblasts were iso-
lated as previously described.18 Myoblasts from patients
with GFPT1 mutations and control myoblasts were ob-
tained from the Medical Research Council (MRC) Centre
for Neuromuscular Diseases Biobank, Newcastle, UK, and
the Muscle Tissue Culture Collection, Friedrich-Baur-Insti-
tut, Munich, Germany, and grown in skeletal muscle
growth medium (PromoCell, Heidelberg, Germany). For
differentiation of myoblasts to myotubes, the growth
medium was removed at a cell density of around 80%
and cells were incubated in DMEM supplemented with
2% horse serum for 7 days.
Transfection of HEK293, SW13, and C2C12 Cells
HEK293 cells were transfected with 3–6 mg of wild-type and
mutated GFPT1 plasmid DNA (with and without
N-terminal Myc tag) with Polyplus jetPEI transfection
reagent (Biomol, Hamburg, Germany) according to the
manufacturer’s recommendations. Transfection of SW13
cells was carried out with FuGene6 transfection reagent
(Roche Diagnostics, Mannheim, Germany) and transfec-
tion of C2C12 cells was performed with Lipofectamine
2000 transfection reagent (Invitrogen, Carlsbad, CA) ac-
cording to the manufacturer’s recommendations. Cells
were analyzed 48 hr after transfection by immunoblot or
immunofluorescence staining.
Preparation of Cell and Muscle Lysates for Protein
Analysis
Cultured cells were scraped off the plastic dish in PBS con-
taining Complete Protease Inhibitor Cocktail Tablets
(Roche Diagnostics) and pelleted by centrifugation
(14,000 rpm, 5 min, 4C). Subsequently, cell pellets were
homogenized in lysis buffer (10 mM Tris-HCl, 1% SDS
[pH 7.4] or PBS with 1% SDS). Muscle biopsy samples
were homogenized in PBS containing protease inhibitors
with a handheld rotor-stator homogenizer (TissueRuptor,
QIAGEN, Hilden, Germany) and SDS was added to the lysis
buffer to a final concentration of 1%. Homogenized cell or
muscle samples were then incubated at 95–100C for
5 min. Debris was removed by 5 min centrifugation at
14,000 rpm and supernatants were used for immunoblot
analysis.
Immunoblot Analysis
Protein concentrations in the extracts were measured with
the BCA protein assay (Thermo Scientific, Waltham, MA).
Protein samples were separated on NuPage Novex 4%–
12% gradient mini gels (Invitrogen) according to the
manufacturer’s guidelines. After gel separation, proteins
were transferred to a polyvinylidene fluoride membrane11, 2011
(GE Healthcare, Buckinghamshire, UK) for 1 hr at 350 mA.
Membranes were washed in Tris buffered saline with
Tween 20(TBS-T) and blocked for 1 hr at room temperature
in TBS-T with 5% nonfat milk. Primary antibodies were
incubated overnight at 4C. The following antibodies
were used: rabbit polyclonal anti-GFPT1 (Proteintech
Group, Chicago, IL; dilution 1:1,000), mouse monoclonal
anti-Myc 9E10 (Clontech, dilution 1:100), mouse mono-
clonal RL2 antibody to O-linked N-acetylglucosamine
(Abcam, Cambridge, MA; dilution 1:1,000), mouse mono-
clonal anti-actin Ab-5 (BD Transduction Laboratories, San
Diego, CA; dilution 1:5,000), and goat polyclonal anti-
actin (Santa Cruz Biotechnology, Santa Cruz, CA; dilution
1:200). Membranes were washed three times for 10 min
with TBS-T and incubated with secondary goat anti-mouse
immunoglobuline G (IgG) antibody conjugated to horse-
radish peroxidase (HRP) (Invitrogen, dilution 1:5,000),
goat anti-rabbit IgG conjugated to HRP (Invitrogen, dilu-
tion 1:5,000), or donkey anti-goat IgG conjugated to HRP
(Jackson ImmunoResearch, West Grove, PA; dilution
1:10,000) for 1 hr at room temperature. Bands were de-
tected with an enhanced chemiluminescence kit (GE
Healthcare) and quantified with the ImageJ program.
125I-a-bungarotoxin Binding
The number of AChRs per motor end plate was estimated
with 125I-a-bungarotoxin binding and AChE staining as
described previously.19
GFPT1 Enzyme Activity Assay
The enzymatic activity of untagged wild-type and mutant
GFPT1 was measured with the glutamate dehydrogenase
method.20,21 HEK293 cells transfected with GFPT1 expres-
sion constructs were lysed in GFPT buffer (50 mMKH2PO4,
10 mM EDTA, 5 mM reduced L-glutathione, 12 mM
D-glucose-6-phosphate Na2, and 1 mM PMSF [pH 7.6]),
and 100 ml aliquots of the lysates were mixed with an equal
volume of the reaction buffer (100 mM KH2PO4, 10 mM
D-fructose 6-phosphate, 6.0 mM L-glutamine, 0.3 mM
3-acetylpyridine adenine dinucleotide, 50 mM KCl, and
6 U L-glutamate dehydrogenase from bovine liver [pH 7.6])
and incubated at 37C for 45 min. The change in absor-
bance was monitored at 370 nm with a Spectra Max
250 microplate reader (Molecular Devices, Sunnyvale,
CA). The enzymatic activity of each mutant was normal-
ized to GFPT1 expression levels determined by immuno-
blot analysis of cell lysates used for enzyme activity
measurements. All transfections and measurements were
done in triplicates.
Zebrafish Husbandry and Observation
We used the wild-type strain *AB (Zebrafish International
Resource Center, Eugene, OR). Zebrafish embryos were
raised and staged according to standard procedures.22,23
Video recordings of embryos and larvae and light micros-
copy images were taken with a Leica dissection stereomi-
croscope equipped with a Moticam 1000 camera (Leica,The AmericaWetzlar, Germany). Touch-evoked swimming response
was elicited by touching the head or the tail of the embryos
with a pipette tip.
Antisense Morpholino Oligonucleotide Knockdown
Antisense morpholino oligonucleotides (MOs) were
purchased from Gene Tools (Pilomath, OR). The MOs
were designed with the mRNA sequence of the zebrafish
GFPT1 ortholog gfpt1 and genomic sequences available
from public databases (GeneID: 567861, accession number:
NM_001034981) and the corresponding genomic DNA
sequence obtained from the zebrafish chromosome 8
assembly.We established twoMOs to target gfpt1, one trans-
lation-blocking MO binding to the region around the start
codon (MO1: 50-TCAGATACGCAAATATGCCACACAT-30)
and one splice-blocking MO directed against the splice
donor site of intron 5 (MO2: 50-TGCTGGAATGTG
TTACTTGCCAGAA-30). MO2 is expected to interfere with
the splicing process and lead to a disruption of the protein
open reading frame and premature translation stop. The
Gene Tools standard control MO (50-CCTCTTACCTCAGT
TACAATTTATA-30) targeting a human b-hemoglobin gene
was used as a negative control for the effects of MO injec-
tion. Embryos were injected with 5–8 ng gfpt1 translation-
blocking MO1, 2–10 ng of gfpt1 splice-blocking MO2 or
15–20 ng of control MO following standard procedures.22,23
Three independent MO injection experiments were per-
formed for each MO and at least 500 injected embryos
were evaluated in total for each MO.
RNA Isolation and RT-PCR
RNA from zebrafish embryos and human cultured
myoblasts, myotubes, or muscle biopsies was isolated
with Trizol reagent (Invitrogen) following the manufac-
turer’s instructions. Reverse transcription was performed
with 1 or 2 mg total RNA as template with the Superscript
III First-Strand Synthesis System (Invitrogen). Regions of
interest in the GFPT1 and gfpt1 cDNA were amplified
with suitable primer sets. For segregation analysis in fami-
lies, PCR products from patients’ cDNA containing GFPT1
mutations were subcloned into the pGEM-T Easy vector
(Promega), and individual clones were isolated and
sequenced.
Immunofluorescence Stainings
For immunofluorescence analysis, cells were grown on
glass coverslips and transfected as described above. Forty-
eight hours after transfection, coverslips were washed in
PBS, fixed in 3.7% formaldehyde in 13 CSK buffer
(100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM
EGTA, and 10 mM PIPES [pH 6.8]) for 10 min at room
temperature, and permeabilized with 0.1% Triton X-100
in 13 CSK buffer for 15 min. After three washes in PBS,
nonspecific binding sites were blocked with PBS contain-
ing 5% horse serum for 1 hr, followed by overnight incuba-
tion at 4C with a mouse monoclonal anti-Myc 9E10 anti-
body (Clontech, dilution 1:100) in PBS with 5% horsen Journal of Human Genetics 88, 162–172, February 11, 2011 165
serum. After three washes in PBS, cells were incubated with
the secondary antibody, goat anti-mouse IgG conjugated
to Alexa Fluor 488 (Invitrogen, dilution 1:500), for 1 hr
at room temperature. Nuclei were visualized with bisbenzi-
mide H 33258 (40 mg/ml). Digital images were captured
with a Zeiss Axiovert 200 M fluorescence microscope and
a Zeiss AxioCam HR photo camera (Zeiss, Oberkochen,
Germany). Whole-mount immunofluorescence staining
and imaging of zebrafish embryos was done as previously
described.24 In brief, NMJ were visualized with Alexa Fluor
594 conjugated a-bungarotoxin (Invitrogen, 1 mg/ml) and
a mouse monoclonal anti-SV2 (synaptic vesicle protein 2)
antibody (Developmental Studies Hybridoma Bank, Iowa
City, IA; dilution 1:200). Slow-twitch muscle fibers were
visualized with amousemonoclonal anti-F59 (slowmuscle
myosin heavy chain, slow MyHC) antibody (Develop-
mental Studies Hybridoma Bank, dilution 1:50).Statistical Analysis
The data show the mean5 SD. Statistical significance was
determined with a two-tailed Student’s t test. Significance
was set at p < 0.05 (*), p < 0.01 (**), or p < 0.001 (***).Results
We had access to 11 so far unreported and 2 previously re-
ported families with limb-girdle CMS with tubular aggre-
gates of various ethnic origins (Figure S2). Direct
sequencing or haplotype analysis excluded all known
genes and loci previously known to be involved in CMS.3
Consanguinity in a Libyan multiplex family with five
affected children (family LGM3) presented the possibility
of locating the disease locus by homozygosity mapping.12
Genome-wide genotyping with approximately 300,000
SNP markers revealed a single hit on chromosome 2p12-
p15 with a maximum LOD score of 3.24 (Figure 1), indi-
cating linkage to this locus. Localization of so far unknown
CMS mutations on chromosome 2p was further supported
by the results of STR marker analysis in additional families
suitable for homozygosity mapping or linkage analysis
(LGM1, LGM2, LGM5, LGM6, LGM7, LGM8, LGM10,
LGM11, and LGM12; Figure S2). Although these pedigrees
were too small to give significant LOD scores, reconstruc-
tion of haplotypes was in full agreement with linkage to
this locus. We systematically exploited the genotyping
data to detect potential recombination events. Under the
assumption of genetic homogeneity, historic recombina-
tion events suggested from regions of homozygosity in
families LGM10 and LGM11 narrowed the critical genetic
interval to a region of interest of 5.92 Mb (Figure S3).
We evaluated and ranked the 46 genes in this region
(Table S1) on the basis of expression pattern and function,
and sequenced the entire coding region and exon-intron
boundaries of 16 genes in the index cases from the three
families that produced the highest LOD scores (LGM1,
LGM3, and LGM10). We identified different homozygous166 The American Journal of Human Genetics 88, 162–172, Februarymissense mutations in the gene encoding GFPT1 in these
three families (Figure 2) and no disease-related changes
in any of the other sequenced genes. We obtained further
evidence for a causative role of GFPT1mutations when ex-
tending GFPT1 mutation screening to the remaining 13
families, yielding biallelic mutations in all pedigrees except
for families LGM4, LGM15, and LGM16 (Figure S4). We
identified a total of 18 different GFPT1 mutations consist-
ing of 13 missense mutations, 3 frameshift mutations, 1
nonsense mutation and 1 variant in the 30-UTR (Figure 2,
Table 1). When DNA from family members was available,
we observed that the disease cosegregated with recessive
inheritance of the GFPT1 mutations. The parents carried
mutations in the heterozygous state, and unaffected
siblings carried either one heterozygous mutation or were
homozygous for the wild-type alleles. When DNA from
family members was not available (families LGM9 and
LGM13), subcloning and sequencing of amplicons from
cDNA derived from muscle biopsies demonstrated that
the mutations were on separate alleles. We observed that
someGFPT1missensemutations caused rathermild amino
acid changes or affected residues that are not strictly
conserved in orthologs (Table 1 and Figure S5). Neverthe-
less, analysis of extended numbers of healthy control indi-
viduals, adjusted to the type of mutation (at least 103 for
each truncating and 221 for each missense mutation; 635
for the 30-UTR variant), did not yield any of the identified
genotypes (Table 1).
We noted that the crystal structures of the Escherichia coli
ortholog for GFPT1 (GlmS) and of the isomerase domain of
human GFPT1 had been solved (Protein Data Bank acces-
sion numbers 2J6H and 2ZJ3).25,26 With this data as the
basis of a structural model for human GFPT1, the
c.1154G>A (p.Arg385His) mutation would be predicted
to impair GFPT1 function because the arginine residue at
position 385 in human GFPT1 corresponds to E. coli
GFPT1 arginine 312, which contributes to the GFPT1
dimer interface. Other GFPT1 missense mutations do not
affect amino acid residues required for oligomerisation or
involved in the catalytic mechanism. Consistent with
this observation, heterologous protein expression of the
GFPT1 mutants p.Thr15Ala, p.Asp43Val and p.Asp348Tyr
had only small effects on enzymatic activity and of the
mutants p.Arg111Cys and p.Arg434His had no effect at
all (Figure S6). We also did not observe any major effect
of the GFPT1 mutations on subcellular localization of the
protein in transfected cells (Figure S6). By contrast, we
found substantially reduced GFPT1 levels in muscle biop-
sies (Figure 2) and cultured primary myoblasts and myo-
tubes obtained from GFPT1 patients (Figure S6). Reduced
amounts of GFPT1 were also seen in patients with the 30-
UTR mutation c.*22C>A (LGM5.5, LGM9.3).
We also set up experiments to follow potential indirect
or direct functional consequences of GFPT1 mutations.
Radiometric assays showed a strongly reduced number of
AchR available for 125I-a-bungarotoxin binding at motor
end-plates of GFPT1 patient LGM8.3 (to around 25% of11, 2011
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Figure 2. Identification of GFPT1 Mutations
(A) GFPT1mutations detected in families used for candidate-gene sequencing. Chromatogram pairs of an unaffected individual and an
affected patient are shown. The asterisks indicate the position of the mutations. Base and amino acid changes with the corresponding
position in the nucleotide and protein sequence are given above chromatograms displaying GFPT1mutations. The numbering of nucle-
otides and amino acids follows NM_002056.2 and NP_002047.2, which represent the short, ubiquitous isoform of GFPT1. Nucleotide
numbering uses the A of the ATG translation initiation start site as nucleotide þ1.
(B) Domain structure of GFPT1 and position of mutations. GFPT1 contains a glutaminase and two sugar isomerase (SIS) domains. The
site of insertion of 18 additional amino acids (hashed box) encoded by a muscle specific exon16 is indicated. Missense mutations are in
black, truncating mutations are in red. The 30-UTR mutation is not shown. The numbering of nucleotides and amino acids is as in (A)
except for the c.719G>A (p.Trp240X) mutation in the muscle specific exon, for which we used numbering of the longer GFPT1-L
sequence.16 aa is an abbreviation for amino acid.
(C) Immunoblot of GFPT1 and O-GlcNAcylation in muscle biopsies of GFPT1 patients. Muscle lysates of patients LGM9.3, LGM5.5,
LGM10.4, and LGM11.3 and two healthy control individuals were immunoblotted with an anti-GFPT1 antibody (top), the RL2 antibody
(detects single N-acetylglucosamine at serine or threonine residues, middle) and an anti-actin antibody (as loading control, bottom).
GFPT1 band intensities were normalized to actin bands in the same lane. Total GFPT1 levels (GFPT1-L and the shorter ubiquitous iso-
form) in patients’ muscles were reduced to 29%, 8%, 9%, and 26% of the level in control muscle 1. The levels of O-linked N-acetylglucos-
amine on proteins were also markedly decreased in patients’ muscles. The membrane was first decorated with the anti-GFPT1 antibody
and later reprobed with the RL2 and anti-actin antibodies.normal). The end product of the hexosamine pathway,
uridine diphospho-N-acetylglucosamine (UDP-GlcNAc),
is involved in multiple glycosylation processes,7 including
the dynamic modification of serine or threonine residues
of intracellular proteins (O-GlcNacylation)27 (Figure S1).
We therefore immunoblotted muscle samples of GFPT1
patients and controls with the RL2 antibody, which selec-
tively detects O-linked N-acetylglucosamine (O-GlcNAc)
residues on numerous proteins.28 As expected, the anti-
body recognized several bands whose intensities were
markedly decreased in muscles from GFPT1 patients
(Figure 2).
In a final series of experiments, we used zebrafish as an
animal model. GFPT1 is conserved in zebrafish, with
high expression levels during early somite development
(data not shown). We knocked down the expression of
the zebrafish GFPT1 ortholog gfpt1 by injection of
antisense MOs, a translation-blocking MO targeting the
region surrounding the start codon (MO1) and a splice-
blocking MO targeting the splice donor site of intron
5 (MO2). Both MOs induced a clear reduction of gfpt1
levels at 48 hr postfertilization (hpf) (Figure S7). Knock-The Americadown of neuromuscular junction proteins usually affects
motility and swimming behavior of injected embryos.
Indeed, MO-injected embryos displayed altered tail
morphology (curled tails and shortened tails, Figure 3),
and swimming and touch-evoked escape response at 48
hpf were severely impaired (Movie S1). Histologically,
we observed abnormal muscle morphology and delayed
NMJ development. Somites had lost their regular
chevron shape with rounding of myosepta to a C shape
instead of the V shape in control embryos. Staining for
slow-twitch muscle fibers revealed morphological abnor-
malities ranging from wavy fibers to severely damaged
fibers that were detached from the vertical myoseptum
(Figure 3). NMJ development progressed normally up to
24 hpf, but from that time point onward, NMJ develop-
ment was delayed. Motor neuron axons had completely
or partially lost their ability to project branches into
laterally located muscle fibers and to form synapses
with them (Figure 3). Both MOs resulted in strikingly
similar phenotypes, whereas embryos injected with
a standard control MO were indistinguishable from non-
injected embryos (data not shown).n Journal of Human Genetics 88, 162–172, February 11, 2011 167
Table 1. GFPT1 Mutations Found in CMS Families
Exon
Nucleotide
Change
Effect
on the
Protein
Families
with This
Mutation
Ethnic
Origin
Number of Control Samples
Granthama SIFTbGerman
Further
Ethnically
Matched Total
2 c.43A>G p.Thr15Ala LGM13 Italy 341 102 Italian 443 58 0.10
2 c.44C>T p.Thr15Met LGM8 UK 324 82 British 406 81 0.01
3 c.128A>T p.Asp43Val LGM6 Germany 223 223 152 0.00
4 c.222_223insA p.Gln76fs LGM14 Sweden 117 117
4 c.331C>T p.Arg111Cys LGM3, LGM14 Libya, Sweden 173 67 North African 240 180 0.03
5 c.362T>C p.Ile121Thr LGM6 Germany 432 432 89 0.01
7 c.595G>T p.Val199Phe LGM9 Germany 425 425 50 0.01
8 c.621_622 del p.Leu208fs LGM13 Italy 45 58 Italian 103
8A c.719G>A p.Trp240X LGM2 Turkey 92 115 Turkish 207
11 c.1042G>T p.Asp348Tyr LGM1 Iran 376 66 Iranian 442 160 0.05
13 c.1154G>A p.Arg385His LGM7 UK 340 97 British 437 29 0.00
14 c.1278_1281 dup p.Asp428fs LGM12 Spain 57 83 Spanish 140
14 c.1301G>A p.Arg434His LGM7 UK 331 95 British 426 29 0.02
15 c.1472T>C p.Met491Thr LGM11 Spain 452 86 Spanish 538 81 0.45
15 c.1475T>C p.Met492Thr LGM5 Spain 327 84 Spanish 411 81 0.01
15 c.1486C>T p.Arg496Trp LGM8 UK 136 85 British 221 101 0.00
15 c.1534C>T p.Arg512Trp LGM10 Senegal 146 84 African American 230 101 0.03
19 c.*22C>A LGM5, LGM9,
LGM12
Spain, Germany 543 92 Spanish 635
The numbering of nucleotides and amino acids follows NM_002056.2 and NP_002047.2 except for the c.719G>A (p.Trp240X) mutation in the muscle specific
exon, for which we used numbering of the longer GFPT1-L sequence, AF334737.1 and AAK15342.1.16
a The Grantham scale categorizes codon replacements into classes of chemical dissimilarity between the encoded amino acids (0–50: conservative; 51–100:
moderately conservative; 101–150: moderately radical; R151: radical).40,41
b Sorting Intolerant from Tolerant (SIFT) predicts the functional importance of amino acid substitutions based on the alignment of orthologous sequences
(0.0-0.05: intolerant; 0.051-0.1: potentially intolerant; 0.101-0.2: borderline; 0.201-1.0: tolerant).42Discussion
In this study, we provide two lines of genetic evidence that
GFPT1, the key enzyme of the hexosamine pathway
yielding essential amino sugars for carbohydrate modifica-
tions, is required for critical events in neuromuscular trans-
mission. Specifically, we localized and refined the genetic
interval for a so far genetically undetermined autosomal
recessive CMS on chromosome 2 and identified GFPT1
mutations as the molecular defect. This finding was reca-
pitulated by a neuromuscular morphant phenotype
observed in zebrafish embryos lacking GFPT1. We found
18 different homozygous and compound heterozygous
GFPT1 mutations in 13 unrelated families, and GFPT1
mutations occurred in CMS cohorts of various ethnic
origins. Although failure to detect mutations in three addi-
tional cases is probably related to so far unexplored muta-
tion mechanisms or involvement of additional unknown
genes, our data indicate that GFPT1 mutations represent
the major cause for limb-girdle CMS with good treatment
response to AChE inhibitors or tubular aggregates in168 The American Journal of Human Genetics 88, 162–172, Februarymuscle biopsies. With respect to genetic diagnosis and
counselling, limb-girdle CMS patients with effective
response to AChE inhibitors or tubular aggregates in
muscle biopsies should undergo GFPT1 sequencing,
whereas all other limb-girdle CMS patients should be
screened for DOK7 mutations first and—if negative—for
GFPT1 mutations.
In metazoa, there are two GFPT genes, GFPT1 and
GFPT2, encoding isozymes with different tissue distribu-
tions.29 GFPTs are homodimeric, cytoplasmic enzymes
that transfer an amino group from glutamine onto fruc-
tose-6-phosphate, yielding glucosamine-6-phosphate
(GlcN-6-P) and glutamate. This reaction is the first and
rate-limiting step of the hexosamine biosynthesis pathway
(Figure S1), which is the obligatory source of essential
building blocks for the glycosylation of proteins and
lipids.7 GFPT1 is the only or predominant isoform in
kidney, pancreas and liver. Because glycosylation is essen-
tial for cell survival, it might be expected that GFPT1muta-
tions create hypomorphic alleles. Indeed none of our
patients carries two null mutations in the constitutive11, 2011
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Figure 3. Gpft1 Knockdown in Zebrafish Embryos
(A–D) Live embryos at 24 and 48 hpf injected with the translation-
blocking gfpt1 antisense morpholino oligo MO1 (A and B) and
noninjected controls (C and D). Note increased tail curvature in
gfpt1 morphants.
(E–P)Whole-mount immunostainings of zebrafish embryos. Slow-
twitch muscle fiber structure in 48 hpf gfpt1-MO1 injected mor-
phants (E–G) and noninjected controls (H–J). Embryos were
stained for AChR (abungarotoxin) and slow-twitch muscle fibers
(anti-slow muscle myosin heavy chain [slow MyHC], F59 anti-
body). Gfpt1 morphants show severe muscle fiber defects with
detachment of fibers from the vertical myoseptum. Somites
have lost their chevron shape. (K–P) Neuromuscular junctions in
48 hpf gfpt1 morphants (K–M) and noninjected controls (N–P).
Embryos were stained for AChR (abungarotoxin) and presyn-
aptic nerve endings (anti-SV2 antibody). In controls, motor axons
have branched out into all parts of the somite where they form
contacts with AChR clusters. In gfpt1-MO1 injected embryos
AChR clusters are predominantly located along the medial surface
of the somite, and motor axons form fewer branches than in
controls. The scale bars represent 50 mm.
The Americaexons of the GFPT1 gene. The homozygous p.Trp240X
mutation (family LGM2) is predicted to lead to decreased
GFPT1 levels only in heart and skeletal muscle as it occurs
in an alternative 18 amino acid exon, exclusively incorpo-
rated in the predominant GFPT1 species in striated
muscle.16 The expected residual function of GFPT1
mutants is also consistent with our finding that some
GFPT1 missense mutations result in amino acids with
similar physicochemical properties or affect residues that
are not strictly conserved in orthologs (Figure S5).
With the notable exception of p.Arg385His, which
potentially affects GFPT1 dimerization, in silico structural
modeling and heterologous expression studies did not
reveal definite pathophysiological effects of GFPT1
mutants. However, protein expression data in patients’
muscle cells and biopsy specimens suggest that GFPT1
mutations may lead to substantially reduced GFPT1 levels.
The mechanism by which the mutants inhibit protein
expression remains to be determined but may involve
reduced levels of GFPT1 mRNA, increased GFPT1 turn-
over, or interference with protein translation. Notably,
the 30-UTR mutation c.*22C>A (patients LGM5.5,
LGM9.3) was also associated with reduced amounts of
GFPT1. For this particular mutation, the combination of
an observed decrease in protein levels, its presence in three
unrelated families, its absence in a large number of control
chromosomes, and compound heterozygosity with a trun-
cating mutation in one family strongly suggests that
c.*22C>A is a disease-causing variant. Nevertheless, the
pathogenic mechanism at the molecular level of
c.*22C>A is not yet clear. Analysis of the GFPT1 skeletal
muscle mRNA by RT-PCR in two patients excluded effects
on splicing and showed similar levels of wild-type and
mutated position c.*22 mRNA expression (Figure S6). It is
possible that this mutation, like many 30-UTR mutations
in other genes, affects translational efficiency.30
Other CMS related genes known to date encode structural
componentsof theneuromuscular junction,whereasGFPT1
is believed toplay amoregeneral role in the cell. Theproduct
of the transamidase reactioncatalyzedbyGFPT1,GlcN-6-P, is
used in thehexosaminepathway to synthesizeUDP-GlcNAc
that serves ascommonprecursor for all aminosugarsused for
the synthesis of glycoproteins, glycolipids, and proteogly-
cans (Figure S1).7 Many key NMJ proteins are glycosylated,8
including MuSK, AChR subunits, agrin, dystroglycan, and
integrins. Interestingly, a missense mutation removing one
of the N-glycosylation sites of the 3 subunit of the AChR
causes CMS.31 Moreover, treatment with tunicamycin (an
inhibitor of protein glycosylation) and in vitro mutations
of AChR subunits that prevent glycosylation severely reduce
cell surface expression of AChR, either through a decrease of
metabolic stability or through a failure in efficient assembly
of the pentameric AChR.32 UDP-GlcNAc is also extensively
involved in intracellular signaling in a wide range of species.
N-acetylglucosamine is reversibly attached to serine or thre-
onine residues of cytoplasmic and nuclear proteins, similar
to phosphorylation (O-GlcNAcylation).27 Reduced endplaten Journal of Human Genetics 88, 162–172, February 11, 2011 169
AChR numbers and decreased protein O-GlcNAcylation in
patients’ muscles observed in our studymay provide a small
glimpseat themolecular andcellularconsequencesofGFPT1
mutations. Lectin stainings, digestions with glycosidases,
antibodies to carbohydrate-linked proteins, or mass spec-
trometry-based techniques are likely to demonstrate specific
changes in protein glycosylation. Identification of such
changes may also help to clarify why, although universally
required, the functions of the NMJ is especially vulnerable
to alterations of the hexosamine pathway.
In order to obtain further proof that a reduction ofGFPT1
levels leads to NMJ or muscle dysfunction, we utilized ze-
brafish as an animal model. Although overall the muscle
structure of zebrafish differs from mammalian muscles,33
NMJ formation occurs in a similar stepwise sequence, and
zebrafish mutants and morphants have previously proved
a good model system for studies of myasthenic syndromes
and NMJ function.24,34–36 Morpholino-mediated knock-
down of gfpt1 in zebrafish embryos induced a neuromus-
cular phenotype and resulted in altered muscle histology
and delayed NMJ maturation. These data provide another
level of genetic evidence and independently confirms that
GFPT1 is required for normal NMJ formation.
Although the precise pathogenic mechanisms involved
remain to be determined, our work highlights amino sugar
metabolism as a pathophysiological mechanism that can
underlie NMJ disorders and paves the way for treatment
options. Because the vertebrate NMJ is a classic model
synapse becasue of its comparatively large size and easy
accessibility,37 further investigation of the role of GFPT1
for NMJ function is likely to also contribute to our under-
standing of synapse development and organization in
general. Although there are no clear-cut associations in
our patients, we note that GFPT1 and the hexosamine
pathways have been implicated in signaling pathways
that may become deregulated in diseases of the immune
system, diabetes mellitus, cancer, cardiovascular disease,
and neurodegenerative diseases.38,39 Our findings give
additional impetus for investigating the role of GFPT1 in
human health and disease.Supplemental Data
Supplemental Data includes seven figures, one table, and one
movie and can be found with this article online at http://www.
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